Sueh-Li Lim

Dr Sueh-Li Lim is a haematologist and researcher affiliated with Monash University’s Australian Centre for Blood Diseases. She holds the position of Adjunct Research Associate and is pursuing a Doctorate by Research. Her clinical appointments include Melbourne Pathology (laboratory haematology), Western Health (clinical haematology), and private practice with the Melbourne Haematology group.

• Institution: Monash University
• School: Faculty of Medicine, Nursing and Health Sciences
• Department: Australian Centre for Blood Diseases
• Role: Adjunct Research Associate

Dr Lim specializes in both malignant and non-malignant haematology, with a strong focus on multiple myeloma. Her research emphasizes patient-centered, holistic care and improving treatment outcomes through innovative clinical trial designs and real-world data analysis. She is particularly interested in salvage therapies for patients who fail initial induction regimens, with ongoing work in minimal residual disease assessment and novel combination therapies.

Her recent research publications and active projects center on multiple myeloma therapeutics, including daratumumab-based regimens and next-generation treatments like belantamab mafodotin and AZD0305. These studies reflect a consistent trend in optimizing treatment pathways for both transplant-eligible and ineligible patients, leveraging adaptive trial designs and real-world registry data.

Dr Lim is the Primary Chief Investigator on two active research projects funded through clinical trial collaborations. These include a Phase 3 study (DREAMM-10) evaluating belantamab mafodotin combinations in newly diagnosed multiple myeloma and a Phase I/II trial assessing AZD0305 in relapsed/refractory cases. While no formal awards are listed, her work has been cited in Scopus and featured in news outlets and academic networks.

She is involved in multicenter collaborations, particularly through the ANZ Myeloma and Related Diseases Registry, and works closely with leading haematologists such as Prof. Andrew Spencer. Dr Lim’s work bridges clinical practice and translational research, contributing significantly to evidence-based advancements in haematological oncology.